Increased platelet expression of glycoprotein IIIa following aspirin treatment in aspirin-resistant but not aspirin-sensitive subjects

British Journal of Clinical Pharmacology

Volumn 78, Issue 2, 2014, Pages 320-328

  Floyd, Christopher N ^a   Goodman, Timothy ^a   Becker, Silke ^a   Chen, Nan ^a   Mustafa, Agnesa ^a   Schofield, Emma ^b   Campbell, James ^b   Ward, Malcolm ^b   Sharma, Pankaj ^c   Ferro, Albert ^a  

^a KING'S COLLEGE LONDON   (United Kingdom)

^b Proteome Sciences Plc   (United Kingdom)

^c IMPERIAL COLLEGE LONDON   (United Kingdom)

Author keywords

aspirin resistance; glycoprotein IIIa; platelets; proteomics

Indexed keywords

11 OXOTHROMBOXANE B2; ACETYLSALICYLIC ACID; ARACHIDONIC ACID; GLYCOPROTEIN IIIA; PROTEOME; 11-DEHYDRO-THROMBOXANE B2; BETA3 INTEGRIN; THROMBOXANE B2;

ADULT; ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; CORONARY ARTERY DISEASE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MASS SPECTROMETRY; PREVALENCE; PRIORITY JOURNAL; PROTEIN EXPRESSION; THROMBOCYTE AGGREGATION; THROMBOCYTE RICH PLASMA; TREATMENT OUTCOME; WESTERN BLOTTING; ANALOGS AND DERIVATIVES; BIOSYNTHESIS; BLOOD; CYTOLOGY; DOSE RESPONSE; DRUG EFFECTS; DRUG RESISTANCE; METABOLISM; NORMAL HUMAN; THROMBOCYTE; URINE;

ADULT; ARACHIDONIC ACID; ASPIRIN; BLOOD PLATELETS; COHORT STUDIES; CORONARY ARTERY DISEASE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG RESISTANCE; FEMALE; HEALTHY VOLUNTEERS; HUMANS; INTEGRIN BETA3; MALE; PLATELET AGGREGATION; THROMBOXANE B2;

EID: 84904874242     PISSN: 03065251     EISSN: 13652125     Source Type: Journal    
DOI: 10.1111/bcp.12335     Document Type: Article

References (37)

1. ISIS-2 (Second International Study of Infarct Survival) Collaborative Group. Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction. Lancet 1988; 2: 349-360.
2. Antiplatelet Trialists' Collaboration. Collaborative overview of randomised trials of antiplatelet therapy-II: maintenance of vascular graft or arterial patency by antiplatelet therapy. BMJ 1994; 308: 159-168.
3. Antiplatelet Trialists' Collaboration. Collaborative overview of randomised trials of antiplatelet therapy-III: reduction in venous thrombosis and pulmonary embolism by antiplatelet prophylaxis among surgical and medical patients. BMJ 1994; 308: 235-246.
4. Antithrombotic Trialists' Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 2002; 324: 71-86.
5. Roth GJ, Majerus PW,. The mechanism of the effect of aspirin on human platelets. I. Acetylation of a particulate fraction protein. J Clin Invest 1975; 56: 624-632.
6. Roth GJ, Stanford N, Majerus PW,. Acetylation of prostaglandin synthase by aspirin. Proc Natl Acad Sci U S A 1975; 72: 3073-3076.
7. Gum PA, Kottke-Marchant K, Poggio ED, Gurm H, Welsh PA, Brooks L, Sapp SK, Topol EJ,. Profile and prevalence of aspirin resistance in patients with cardiovascular disease. Am J Cardiol 2001; 88: 230-235.
8. McKee SA, Sane DC, Deliargyris EN,. Aspirin resistance in cardiovascular disease: a review of prevalence, mechanisms, and clinical significance. Thromb Haemost 2002; 88: 711-715.
9. Hovens MM, Snoep JD, Eikenboom JC, van der Bom JG, Mertens BJ, Huisman MV,. Prevalence of persistent platelet reactivity despite use of aspirin: a systematic review. Am Heart J 2007; 153: 175-181.
10. Bhatt DL, Topol EJ,. Scientific and therapeutic advances in antiplatelet therapy. Nat Rev Drug Discov 2003; 2: 15-28.
11. Goodman T, Sharma P, Ferro A,. The genetics of aspirin resistance. Int J Clin Pract 2007; 61: 826-834.
12. Born GV,. Aggregation of blood platelets by adenosine diphosphate and its reversal. Nature 1962; 194: 927-929.
13. Michelson AD, Frelinger AL III, Furman MI,. Current options in platelet function testing. Am J Cardiol 2006; 98: S4-10.
14. Mammen EF, Alshameeri RS, Comp PC,. Preliminary data from a field trial of the PFA-100 system. Semin Thromb Hemost 1995; 21 (Suppl. 2): 113-121.
15. Hayward CP, Harrison P, Cattaneo M, Ortel TL, Rao AK,. Platelet function analyzer (PFA)-100 closure time in the evaluation of platelet disorders and platelet function. J Thromb Haemost 2006; 4: 312-319.
16. Smith JW, Steinhubl SR, Lincoff AM, Coleman JC, Lee TT, Hillman RS, Coller BS,. Rapid platelet-function assay: an automated and quantitative cartridge-based method. Circulation 1999; 99: 620-625.
17. Cattaneo M,. Aspirin and clopidogrel: efficacy, safety, and the issue of drug resistance. Arterioscler Thromb Vasc Biol 2004; 24: 1980-1987.
18. Damas JK, Waehre T, Yndestad A, Otterdal K, Hognestad A, Solum NO, Gullestad L, Froland SS, Aukrust P,. Interleukin-7-mediated inflammation in unstable angina: possible role of chemokines and platelets. Circulation 2003; 107: 2670-2676.
19. Nadar S, Blann AD, Lip GY,. Effects of aspirin on intra-platelet vascular endothelial growth factor, angiopoietin-1, and p-selectin levels in hypertensive patients. Am J Hypertens 2006; 19: 970-977.
20. Boncler M, Luzak B, Rozalski M, Golanski J, Rychlik B, Watala C,. Acetylsalicylic acid is compounding to antiplatelet effect of C-reactive protein. Thromb Res 2007; 119: 209-216.
21. Lopez-Farre AJ, Mateos-Caceres PJ, Sacristan D, Azcona L, Bernardo E, de Prada TP, Alonso-Orgaz S, Fernandez-Arguero M, Fernandez-Ortiz A, Macaya C,. Relationship between vitamin D binding protein and aspirin resistance in coronary ischemic patients: a proteomic study. J Proteome Res 2007; 6: 2481-2487.
22. Favaloro EJ,. Clinical utility of the PFA-100. Semin Thromb Hemost 2008; 34: 709-733.
23. Thompson A, Schäfer J, Kuhn K, Kienle S, Schwarz J, Schmidt G, Neumann T, Johnstone R, Mohammed AK, Hamon C,. Tandem mass tags: a novel quantification strategy for comparative analysis of complex protein mixtures by MS/MS. Anal Chem 2003; 75: 1895-1904.
24. Sinclair J, Timms JF,. Quantitative profiling of serum samples using TMT protein labelling, fractionation and LC-MS/MS. Methods 2011; 54: 361-369.
25. Engmann O, Campbell J, Ward M, Giese KP, Thompson AJ,. Comparison of a protein-level and peptide-level labeling strategy for quantitative proteomics of synaptosomes using isobaric tags. J Proteome Res 2010; 9: 2725-2733.
26. Hankey GJ, Eikelboom JW,. Aspirin resistance. Lancet 2006; 367: 606-617.
27. Lordkipanidze M, Pharand C, Schampaert E, Turgeon J, Palisaitis DA, Diodati JG,. A comparison of six major platelet function tests to determine the prevalence of aspirin resistance in patients with stable coronary artery disease. Eur Heart J 2007; 28: 1702-1708.
28. Macchi L, Christiaens L, Brabant S, Sorel N, Ragot S, Allal J, Mauco G, Brizard A,. Resistance in vitro to low-dose aspirin is associated with platelet PlA1 (GP IIIa) polymorphism but not with C807T(GP Ia/IIa) and C-5T Kozak (GP Ibalpha) polymorphisms. J Am Coll Cardiol 2003; 42: 1115-1119.
29. Fontana P, Nolli S, Reber G, de Moerloose P,. Biological effects of aspirin and clopidogrel in a randomized cross-over study in 96 healthy volunteers. J Thromb Haemost 2006; 4: 813-819.
30. Bernardo E, Angiolillo DJ, Ramirez C, Cavallari U, Trabetti E, Sabate M, Hernandez R, Moreno R, Escaned J, Alfonso F, Banuelos C, Costa MA, Bass TA, Pignatti PF, Macaya C, Fernandez-Ortiz A,. Lack of association between gene sequence variations of platelet membrane receptors and aspirin responsiveness detected by the PFA-100 system in patients with coronary artery disease. Platelets 2006; 17: 586-590.
31. Gurbel PA, Bliden KP, DiChiara J, Newcomer J, Weng W, Neerchal NK, Gesheff T, Chaganti SK, Etherington A, Tantry US,. Evaluation of dose-related effects of aspirin on platelet function: results from the Aspirin-Induced Platelet Effect (ASPECT) study. Circulation 2007; 115: 3156-3164.
32. Lee PY, Chen WH, Ng W, Cheng X, Kwok JY, Tse HF, Lau CP,. Low-dose aspirin increases aspirin resistance in patients with coronary artery disease. Am J Med 2005; 118: 723-727.
33. Ross PL, Huang YN, Marchese JN, Williamson B, Parker K, Hattan S, Khainovski N, Pillai S, Dey S, Daniels S, Purkayastha S, Juhasz P, Martin S, Bartlet-Jones M, He F, Jacobson A, Pappin DJ,. Multiplexed protein quantitation in Saccharomyces cerevisiae using amine-reactive isobaric tagging reagents. Mol Cell Proteomics 2004; 3: 1154-1169.
34. Choe L, D'Ascenzo M, Relkin NR, Pappin D, Ross P, Wiliamson B, Guertin S, Pribil P, Lee KH,. 8-plex quantitation of changes in cerebrospinal fluid protein expression in subjects undergoing intravenous immunoglobulin treatment for Alzheimer's disease. Proteomics 2007; 7: 3651-3660.
35. Casey T, Solomon PS, Bringans S, Tan KC, Oliver RP, Lipscombe R,. Quantitative proteomic analysis of G-protein signalling in Stagonospora nodorum using Isobaric Tags for Relative and absolute quantification (iTRAQ). Proteomics 2010; 10: 38-47.
36. Frelinger AL 3rd, Li Y, Linden MD, Barnard MR, Fox ML, Christie DJ, Furman MI, Michelson AD,. Association of cyclooxygenase-1-dependent and -independent platelet function assays with adverse clinical outcomes in aspirin-treated patients presenting for cardiac catheterization. Circulation 2009; 120: 2586-2596.
37. Simpson SH, Abdelmoneim AS, Omran D, Featherstone TR,. Prevalence of high on-treatment platelet reactivity in diabetic patients treated with aspirin. Am J Med 2014; 127: 95.e1-959.